Septerna to Present at TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Septerna (Nasdaq: SEPN) announced that CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 p.m. ET in Boston.

A live webcast will be available on the company investor website and will be archived for at least 30 days for on-demand viewing.

Key Figures

Conference edition: 46th Presentation date: March 3, 2026 Presentation time: 3:10 p.m. ET +1 more

4 metrics

Conference edition 46th TD Cowen Annual Health Care Conference

Presentation date March 3, 2026 Scheduled conference presentation in Boston

Presentation time 3:10 p.m. ET Scheduled time of company presentation

Webcast archive period 30 days Duration webcast will remain available after presentation

Market Reality Check

Price: $28.00 Vol: Volume 263,581 is at 0.87...

normal vol

$28.00 Last Close

Volume Volume 263,581 is at 0.87x the 20-day average of 304,369, indicating slightly lighter-than-normal trading ahead of the conference. normal

Technical Shares at $28.00 are trading above the 200-day moving average of $18.21 and about 10.7% below the 52-week high of $31.37.

Peers on Argus

Momentum scanner shows mixed moves among biotech peers, with names like PVLA and...

2 Up 1 Down

Momentum scanner shows mixed moves among biotech peers, with names like PVLA and VIR up strongly while SVRA is down. With scanner flagging is_sector_move = false and no same-day peer news, trading in SEPN appears more stock-specific than part of a broad sector rotation.

Historical Context

5 past events · Latest: Feb 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Inducement option grant	Neutral	-1.4%	Inducement stock option grant to new Chief Legal Officer under Nasdaq rule.
Feb 10	Clinical data presentation	Positive	+0.4%	Announcement of Phase 1 SEP-631 data presentation at 2026 AAAAI meeting.
Jan 08	Leadership appointment	Positive	-1.7%	Appointment of industry veteran Mark A. Wilson as Chief Legal Officer.
Dec 17	JP Morgan conference	Neutral	+1.2%	Planned CEO presentation at 44th Annual J.P. Morgan Healthcare Conference.
Nov 25	Evercore conference	Neutral	-1.9%	Participation in fireside chat at 8th Annual Evercore Healthcare Conference.

Pattern Detected

Recent news has mostly involved conferences, leadership changes, and equity awards. Price reactions have been modest and sometimes moved opposite to seemingly constructive updates, suggesting limited but occasionally contrarian trading around routine corporate news.

Recent Company History

This announcement continues a pattern of visibility and corporate updates for Septerna. Recent items include multiple stock option grants on February 6, 2026, a leadership expansion with a new Chief Legal Officer on January 8, 2026, and participation in high-profile conferences such as the 44th Annual J.P. Morgan Healthcare Conference and the 8th Annual Evercore Healthcare Conference. Price moves around these events were generally modest, indicating that the market has treated them as incremental rather than transformational.

Market Pulse Summary

This announcement highlights Septerna’s continued visibility efforts through participation in the TD...

Analysis

This announcement highlights Septerna’s continued visibility efforts through participation in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company has a track record of presenting at major industry meetings and sharing clinical progress via webcasts archived for at least 30 days. Investors may focus on messaging around pipeline strategy, timelines, and any incremental clinical or corporate details shared during the presentation.

Key Terms

g protein-coupled receptor, gpcr

2 terms

g protein-coupled receptor medical

"pioneering a new era of G protein-coupled receptor (GPCR) drug discovery"

A G protein-coupled receptor is a protein on a cell’s surface that acts like an antenna: it detects signals such as hormones, neurotransmitters or drugs outside the cell and passes that message inside to change cell behavior. Investors care because roughly a third of marketed medicines act on these receptors, so a company’s success in targeting or modulating a specific receptor can determine the value of drug candidates, regulatory risk, and future revenue potential.

gpcr medical

"pioneering a new era of G protein-coupled receptor (GPCR) drug discovery"

G protein-coupled receptors (GPCRs) are a large family of proteins on cell surfaces that act like locks sensing chemical signals — when the right key binds, they trigger internal cell responses. They matter to investors because GPCRs are the target of many marketed drugs and experimental therapies; success or failure in developing a GPCR-targeting drug can change a company’s revenue prospects, clinical progress, and licensing value, much like winning control of a widely used distribution channel.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46^th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston.

A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform^® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

FAQ

When will Septerna (SEPN) present at the TD Cowen 46th Annual Health Care Conference?

Septerna will present at TD Cowen on March 3, 2026, at 3:10 p.m. ET in Boston. According to the company, CEO Jeffrey Finer, M.D., Ph.D., will deliver the presentation and represent the company to investors and analysts.

How can investors watch the Septerna (SEPN) presentation on March 3, 2026?

Investors can watch a live webcast on Septerna’s investor website during the March 3, 2026 presentation. According to the company, the webcast link will be posted on the investor section of septerna.com for real-time viewing.

Who will present for Septerna (SEPN) at the TD Cowen conference?

Jeffrey Finer, M.D., Ph.D., CEO and co-founder, will present Septerna’s session at TD Cowen on March 3, 2026. According to the company, Dr. Finer will discuss company progress and strategic updates during the scheduled timeslot.

Will the Septerna (SEPN) webcast be archived after the March 3 presentation and for how long?

Yes; Septerna will archive the March 3, 2026 presentation webcast for at least 30 days following the live event. According to the company, the archived webcast will be accessible via the investor section of septerna.com for on-demand playback.

What topics will Septerna (SEPN) cover during the TD Cowen presentation on March 3, 2026?

Septerna is expected to discuss its GPCR drug discovery platform and ongoing clinical-stage programs during the March 3 presentation. According to the company, CEO Jeffrey Finer will present program progress, development milestones, and the company’s strategic outlook to investors.